Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Panel Votes Against First-line Use For Luitpold’s Iron Deficiency Drug Injectafer

This article was originally published in PharmAsia News

Executive Summary

The U.S. FDA's Drug Safety and Risk Management Advisory Committee will not recommend that the agency approve Daiichi Sankyo's U.S. subsidiary Luitpold's Injectafer for first-line treatment of iron deficiency anemia in postpartum patients and those with heavy uterine bleeding, the panel decided at its Feb. 1 meeting
Advertisement

Related Content

Daiichi/Luitpold’s Injectafer “Not Approvable”
Daiichi/Luitpold’s Injectafer “Not Approvable”
U.S. FDA Panel Mulls Safety Of Luitpold’s Intravenous Iron
U.S. FDA Panel Mulls Safety Of Luitpold’s Intravenous Iron
Advertisement
UsernamePublicRestriction

Register

SC067819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel